The Most Popular Pill in America
One in three American adults swallows a multivitamin most days, with disease prevention named as the primary motivation.
The logic feels airtight: micronutrients are genuinely essential, sailors died of scurvy without vitamin C, whole populations fell to beriberi before thiamine, and if deficiency kills, a daily top-up must protect.
A multivitamin is nutritional insurance against risks you cannot see, which helps explain $69.3 billion in American supplement spending in 2024, per Nutrition Business Journal.
It buys peace of mind. The longevity is another matter.
390,124 People, 27 Years, Zero Benefit
Erikka Loftfield of the National Cancer Institute's Division of Cancer Epidemiology and Genetics pooled three of the largest prospective cohorts in American epidemiology: the NIH-AARP Diet and Health Study, the PLCO Cancer Screening Trial, and the Agricultural Health Study.
The combined 390,124 adults were healthy at enrollment, with no history of cancer or chronic disease; use was recorded in 1993-2001, reassessed in 1998-2004, and follow-up ran up to 27 years, during which 164,762 participants died.
That death toll gave the analysis enormous power to detect even a small survival advantage. There was none.
Daily use was not associated with lower all-cause mortality in either half of follow-up, nor with lower cancer, heart disease, or cerebrovascular mortality, after adjustment for demographics, diet quality, smoking, and more.
The detail that should trouble believers most is who took the pills: users were healthier at baseline, more likely to be women, more likely to be college educated, less likely to smoke. This is healthy-user bias, which normally flatters the pill, since the kind of person who takes vitamins is the kind who lives longer for other reasons. The bias favored the multivitamin, yet the benefit never appeared.
The Four Percent That Wasn't the Point
In the time-varying analysis of 234,593 participants with two assessments, daily users showed a 4% higher mortality risk in the first follow-up period (hazard ratio 1.04, 95% CI 1.02-1.07); the second-period estimate was 0.98, indistinguishable from no effect.
Read that pattern the way the authors do: a risk that appears early and vanishes later is the fingerprint of reverse causation, because people who sense declining health start taking vitamins, some die in the early years, and the pill takes the statistical blame for the illness that prompted it.
Epidemiologists call it the sick-user effect. The team designed around it, excluding baseline chronic disease and running lagged analyses, though some residue likely survived.
The signal has precedent in the Iowa Women's Health Study, which previously linked multivitamin use to slightly higher mortality in older women.
It also deserves a human-scale anchor: a 4% relative bump on a roughly 1.5% annual death risk adds about six hundredths of a percentage point, which is not a poisoning but a statistical whisper, consistent with no benefit rather than evidence of harm.
The Six-Billion-Dollar Null Result
Nobody ran the population math, so here it is: roughly 260 million American adults, one in three using a multivitamin, puts the user base near 86 million, and a store-brand daily multi costs about twenty cents a day, or $73 a year.
Eighty-six million times $73 is roughly $6.3 billion per year; at ten cents a day the figure is $3.1 billion, at forty cents $12.6 billion. These are back-of-the-envelope inputs, stated so you can check them.
The conclusion survives any reasonable price: Americans spend several billion dollars yearly on a longevity intervention with no measured longevity benefit.
The cost-effectiveness ratio is the bleak punchline, because dividing dollars spent by life-years gained, with zero in the denominator, leaves the ratio undefined: every dollar buys exactly zero measured extra life.
Insurance against a risk you do not have is not insurance. It is a subscription.
The Strongest Case Against
The deepest objection is the design: no adjustment turns observation into a randomized trial, so the 4% early signal is almost certainly residual confounding, and a skeptic may fairly say the study shows what kind of people take the pill, not what the pill does.
The second objection is the calendar. Baseline use was measured in 1993-2001, in cohorts older and whiter than America today, and formulations have changed; a null in yesterday's pills may not describe today's gummies.
The third objection is the endpoint, because mortality is not everything, and here randomized evidence cuts the other way: COSMOS randomized 21,442 older adults to a daily multivitamin or placebo, found no effect on cardiovascular disease, cancer, or death, yet a 2024 meta-analysis of its cognitive substudies found users gained 0.07 standard deviations of global cognition, about two fewer years of cognitive aging.
One critic questions those substudies' methods, and the effect is small; still, it is randomized evidence, and the honest pitch for the pill may be a slightly sharper 80-year-old brain rather than a longer life.
The fourth objection is the outlier: the Physicians' Health Study II randomized 14,641 male physicians, found no cardiovascular benefit, and reported a borderline 8% reduction in total cancer in a companion analysis, the most cited positive result in a literature the accompanying JAMA editorial judges mostly negative.
What We Didn't Prove
Observational data cannot prove a negative, and this study cannot speak to the people it excluded: anyone with a diagnosed deficiency, pregnant women taking folic acid, or patients with absorption problems after bariatric surgery, for whom targeted supplementation is real medicine.
Use was self-reported, formulations varied, the cohorts do not represent all Americans, and other aging outcomes were not the endpoint.
The honest summary is narrower than the headline: among generally healthy adults, daily multivitamin use is not associated with living longer.
The Bottom Line
The multivitamin is nutritional insurance sold to people already covered; if you eat reasonably well, your body holds the policies the pill duplicates.
Twenty-seven years of follow-up in 390,124 people could not find a single extra day of life the pill had purchased.
The 4% signal reads as an epitaph for the hype, not a warning about the pill: people who feel illness approaching reach for vitamins, and the vitamins did not summon the illness.
Keep the bottle if the ritual comforts you, but stop calling it an investment in longevity.
What You Can Do
First, if you take a daily multi to live longer, redirect the effort: the accompanying editorial points to the Nurses' Health Study and the Health Professionals Follow-up Study, where the mortality benefits people want from the pill appear in people eating five or more daily servings of fruits and vegetables.
Food delivers micronutrients plus fiber and better fats, which no tablet replicates.
Second, keep taking what your doctor prescribed; deficiency, pregnancy, and malabsorption are a different universe from healthy-adult longevity hacking.
Third, if you are over 60 and worried about your mind, the COSMOS cognitive finding is the one evidence-based conversation worth having with your doctor.
Fourth, apply the healthy-user test to your habits: the pill was mostly a marker of conscientiousness, and if you are conscientious enough to take one daily, you are conscientious enough to benefit from the habits it was standing in for.